Cardiovascular disease (CVD) and chronic kidney disease (CKD) have become leading health problems worldwide. In addition, both conditions have relevant interrelatioships: cardiovascular disease may promote the development and progression of CKD, whereas CKD is a cardiovascular risk factor per se and potentiate the harmful effects of other cardiovascular risk factors. In addition, a critical common pathogenic and pathophysiologic factor in CVD and CKD is the renin-angiotensin-aldosterone system (RAAS). Moreover, from a therapeutic perspective, blockade of RAAS is a pivotal strategy in the treatment, control and prevention of CVD and CKD. Cardiovascular disease (CVD) represents a leading health problem and a significant economic burden on society. It is the leading cause of death in the U.S., accounting for more than 35% of deaths. Significant vascular risk factors for CVD include hypertension, diabetes, dyslipidemia, tobacco use, microalbuminuria, glomerular filtration rate (GFR) less than 60 ml/m, a family history of CVD, physical inactivity, and obesity. All of the risk factors mentioned contribute to a continuum of vascular disease, atherosclerosis, coronary artery disease, and left ventricular hypertrophy. The result is myocardial infarction with consequent remodeling of the myocardium, heart failure (HF), and arrhythmias, all contributing to premature death.